846 related articles for article (PubMed ID: 30344100)
1. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Yan HHN; Siu HC; Law S; Ho SL; Yue SSK; Tsui WY; Chan D; Chan AS; Ma S; Lam KO; Bartfeld S; Man AHY; Lee BCH; Chan ASY; Wong JWH; Cheng PSW; Chan AKW; Zhang J; Shi J; Fan X; Kwong DLW; Mak TW; Yuen ST; Clevers H; Leung SY
Cell Stem Cell; 2018 Dec; 23(6):882-897.e11. PubMed ID: 30344100
[TBL] [Abstract][Full Text] [Related]
2. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
3. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
[TBL] [Abstract][Full Text] [Related]
4. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
[TBL] [Abstract][Full Text] [Related]
5. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.
Li J; Xu H; Zhang L; Song L; Feng D; Peng X; Wu M; Zou Y; Wang B; Zhan L; Hua G; Zhan X
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2637-2647. PubMed ID: 31598791
[TBL] [Abstract][Full Text] [Related]
6. An Organoid-Based Preclinical Model of Human Gastric Cancer.
Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
[TBL] [Abstract][Full Text] [Related]
7. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
[TBL] [Abstract][Full Text] [Related]
8. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
9. Prospective derivation of a living organoid biobank of colorectal cancer patients.
van de Wetering M; Francies HE; Francis JM; Bounova G; Iorio F; Pronk A; van Houdt W; van Gorp J; Taylor-Weiner A; Kester L; McLaren-Douglas A; Blokker J; Jaksani S; Bartfeld S; Volckman R; van Sluis P; Li VS; Seepo S; Sekhar Pedamallu C; Cibulskis K; Carter SL; McKenna A; Lawrence MS; Lichtenstein L; Stewart C; Koster J; Versteeg R; van Oudenaarden A; Saez-Rodriguez J; Vries RG; Getz G; Wessels L; Stratton MR; McDermott U; Meyerson M; Garnett MJ; Clevers H
Cell; 2015 May; 161(4):933-45. PubMed ID: 25957691
[TBL] [Abstract][Full Text] [Related]
10. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
11. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
[TBL] [Abstract][Full Text] [Related]
12. Human gastric cancer modelling using organoids.
Seidlitz T; Merker SR; Rothe A; Zakrzewski F; von Neubeck C; Grützmann K; Sommer U; Schweitzer C; Schölch S; Uhlemann H; Gaebler AM; Werner K; Krause M; Baretton GB; Welsch T; Koo BK; Aust DE; Klink B; Weitz J; Stange DE
Gut; 2019 Feb; 68(2):207-217. PubMed ID: 29703791
[TBL] [Abstract][Full Text] [Related]
13. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
[TBL] [Abstract][Full Text] [Related]
15. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
16. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
17. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
18. Xenograft and organoid models in developing precision medicine for gastric cancer (Review).
Xu J; Yu B; Wang F; Yang J
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390969
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
Pauli C; Moch H; Rubin MA
Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
[TBL] [Abstract][Full Text] [Related]
20. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
